预约演示
更新于：2025-05-23
Citicoline
胞磷胆碱
更新于：2025-05-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H26N4O11P2 |
InChIKeyRZZPDXZPRHQOCG-OJAKKHQRSA-N |
CAS号987-78-0 |
关联
62
项与 胞磷胆碱 相关的临床试验IRCT20171116037503N3
Evaluating the effect of Citicoline on development of preterm infants with intraventricular hemorrhage admitted in neonatal intensive care units
PACTR202409776910334
Effect of Selenium and Citicoline versus Zinc and Citicoline versus Citicoline Only on Postoperative Brain Tumor Excision in the ICU
IRCT20240107060637N1
The study of Optical coherence tomography and Optical coherence tomography angiography of the patients with Non-Arteritic Anterior Ischemic Optic Neuropathy before and after receiving Citicoline
100 项与 胞磷胆碱 相关的临床结果
登录后查看更多信息
100 项与 胞磷胆碱 相关的转化医学
登录后查看更多信息
100 项与 胞磷胆碱 相关的专利（医药）
登录后查看更多信息
2,149
项与 胞磷胆碱 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
The synergistic effects of citicoline and silymarin on liver injury and thyroid hormone disturbances in γ-irradiated rats
Article
作者: Ibrahim, Ehab A ; Abdel-Aziz, Nahed ; El-Bahkery, Azza
BACKGROUND:
Exposure to ionizing radiation is inevitable due to its extensive use in industrial and medical applications. The search for effective and safe natural therapeutic agents as alternatives to chemical drugs is crucial to mitigate their side effects. This study aimed to evaluate the effects of citicoline as a standalone treatment or in combination with the anti-hepatotoxic drug silymarin in protecting against liver injury caused by γ-radiation in rats.
METHODS AND RESULTS:
The rats were exposed to γ-radiation (7 Gy) and treated with citicoline (300 mg/kg/day) and/or silymarin (50 mg/kg/day). The results showed that citicoline alleviated liver damage in irradiated rats by reducing hepatic malondialdehyde levels, serum aspartate aminotransferase activity, and inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and nuclear factor-kappa B (NF-κB). It also increased acetylcholine (ACh) levels and the gene expression of the anti-inflammatory protein α7 nicotinic acetylcholine receptor (α7nAChR). Additionally, citicoline improved serum triiodothyronine (T3) levels, thyroid hormone receptor beta (TRβ) gene expression, and iodothyronine deiodinase type 1 activity in hepatic tissues of irradiated rats. Furthermore, citicoline enhanced the effects of silymarin on thyroxine (T4), TRβ, ACh, and α7nAChR when co-administered in irradiated rats. Histopathological analysis confirmed these findings, demonstrating improved liver tissue structure.
CONCLUSIONS:
Citicoline mitigates γ-radiation-induced liver damage by reducing oxidative stress, activating the cholinergic anti-inflammatory pathway, and modulating thyroid hormone metabolism. These findings support the use of citicoline as a safe standalone treatment or as an adjuvant with silymarin for managing liver damage and thyroid hormone disturbances caused by γ-irradiation.
2025-07-01FOOD CHEMISTRY
Characteristics of lipid accumulation induced by high-altitude environment improve the total antioxidant capacity of Ophiocordyceps sinensis
Article
作者: Wang, Tao ; Li, Yuling ; He, Min ; Xiao, Mengjun ; Tang, Chuyu ; Li, Xiuzhang
Ophiocordyceps sinensis is a traditional Chinese herbal medicine and nutritional supplement, which is rich in functional components beneficial to health. The biosynthesis of these components is affected by environment factors, especially lipids. This study analyzed the lipid mass spectrometry characteristics and total antioxidant capacity (TAC) of O. sinensis in 5 different altitude environments and explored the important contributions of environmental factors. The pathway of glycerophospholipid metabolism and biosynthesis of secondary metabolites in O. sinensis was activated by altitude (AM) and mean annual temperature (MAT) at high altitudes. This stimulated the degradation of triglycerides (TG) and the biosynthesis of phosphatidylcholine (PC), and phosphatidylethanolamine (PE), promoted the accumulation of free radical scavenging (FRS) abilities and antioxidant components (AC), and increased its TAC. This study reflects the important role of high altitude environment on lipid metabolism and the formation of bioactive components in O. sinensis and provides a scientific basis for exploring its medicinal value and nutritional value.
2025-05-24Journal of biomolecular structure & dynamics
Repurposing FDA-approved drugs as NLRP3 inhibitors against inflammatory diseases: machine learning and molecular simulation approaches
Article
作者: Agarwal, Vipul ; Raj, Vinit ; Haldhar, Rajesh ; Lee, Sangkil ; Ahmed, Bilal ; Hirad, Abdurahman Hajinur ; Gupta, Anugya ; Han, Sang Beom
Activation of NLRP3 (NOD-like receptor family, pyrin domain-containing protein 3) has been associated with multiple chronic pathologies, including diabetes, atherosclerosis, and rheumatoid arthritis. Moreover, histone deacetylases (HDACs), specifically HDAC6 is required for the NLRP3 inflammasome to assemble and activate. Thus, NLRP3 serves as an attractive target for the development of novel therapeutic approaches. Several companies are now attempting to develop specific modulators of the NLRP3 inflammasome, but only a handful of small molecules of NLRP3 inflammasome inhibitors, such as MCC950 and Tranilast, are currently available for clinical use. However, their use is limited due to severe side effects and short half-lives. Thus, the repurposing of FDA-approved drugs with NLRP3 inhibitory activity is needed. The present study was aimed at repurposing preexisting drugs that might act as safe and effective NLRP3 inhibitors. A library of 2,697 FDA-approved drugs was screened for binding with NLRP3 (PDB: 7ALV) using Glide (Schrödinger). The top seven FDA-approved drugs with potential binding affinities were selected based on docking scores and subjected to ADMET profiling using pkCSM and SwissADME. The binding of the ADMET-favorable FDA-approved drugs to NLRP3 was validated using MMGBSA (Prime) and Molecular Dynamics (Desmond) in the Schrödinger suite. ADMET profiling revealed that of the seven best docking drugs, empagliflozin and citicoline had good drug-likeness properties. Moreover, MMGBSA analysis and molecular dynamics demonstrated that empagliflozin and citicoline exhibited stable ligand-NLRP3 interactions in the presence of solvents. This study sheds light on the ability of various FDA-approved drugs to act as NLRP3 inhibitors.
100 项与 胞磷胆碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 意识障碍 | 日本 | 1981-09-01 | |
| 胰腺炎 | 日本 | 1981-09-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性缺血性卒中 | 临床3期 | 德国 | 2006-10-01 | |
| 急性缺血性卒中 | 临床3期 | 葡萄牙 | 2006-10-01 | |
| 急性缺血性卒中 | 临床3期 | 西班牙 | 2006-10-01 | |
| 大脑中动脉梗塞 | 临床3期 | 德国 | 2006-10-01 | |
| 大脑中动脉梗塞 | 临床3期 | 葡萄牙 | 2006-10-01 | |
| 大脑中动脉梗塞 | 临床3期 | 西班牙 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 96 | Placebo (Placebo) | 鏇襯膚蓋壓衊憲積顧窪(簾襯築鹽壓蓋壓觸選窪) = 選構鏇築選鹹範淵願窪 膚鹽獵積鹹憲壓齋鹹憲 (憲獵構夢願鏇窪積衊範, 4.68) 更多 | - | 2024-10-09 | ||
(Citicoline) | 鏇襯膚蓋壓衊憲積顧窪(簾襯築鹽壓蓋壓觸選窪) = 窪網觸網壓觸醖膚顧簾 膚鹽獵積鹹憲壓齋鹹憲 (憲獵構夢願鏇窪積衊範, 3.84) 更多 | ||||||
N/A | 222 | 構鬱網廠選製繭獵夢餘(構窪壓夢範壓齋廠壓膚) = 淵糧範網鹹網膚選糧選 鬱衊繭積醖鏇壓艱蓋鹽 (艱範鏇選築製膚遞顧鬱 ) | 积极 | 2024-02-22 | |||
構鬱網廠選製繭獵夢餘(構窪壓夢範壓齋廠壓膚) = 餘衊衊鏇餘鑰範艱製壓 鬱衊繭積醖鏇壓艱蓋鹽 (艱範鏇選築製膚遞顧鬱 ) | |||||||
N/A | - | 憲壓淵淵繭獵選鑰製淵(鹽獵遞觸製膚顧醖齋壓) = 齋鏇襯襯遞糧衊廠築鏇 鹹糧膚觸襯積獵製顧齋 (廠遞觸顧夢餘鹽製夢顧 ) 更多 | 积极 | 2023-04-23 | |||
N/A | - | 107 | 糧願襯鏇鏇醖廠簾艱鹹(簾蓋憲窪窪齋醖顧蓋襯) = 簾繭餘鬱網鏇觸醖鬱艱 糧網遞淵膚繭鏇廠餘繭 (襯選鑰鬱鏇夢鹹簾顧憲 ) | - | 2021-06-01 | ||
Placebo | 糧願襯鏇鏇醖廠簾艱鹹(簾蓋憲窪窪齋醖顧蓋襯) = 蓋廠膚餘構壓衊鏇襯構 糧網遞淵膚繭鏇廠餘繭 (襯選鑰鬱鏇夢鹹簾顧憲 ) | ||||||
N/A | 40 | 膚鹽構蓋醖夢願積範蓋(衊齋選鹹選鬱獵觸壓網) = 鏇積餘窪餘築襯願網齋 衊醖構網壓膚築鹽築醖 (蓋膚製廠鏇壓糧衊網齋, 鬱膚憲衊糧蓋繭齋鏇餘 ~ 蓋築襯鑰襯襯積築網鏇) 更多 | - | 2021-04-22 | |||
临床4期 | 62 | Placebo (Placebo) | 齋夢糧顧壓觸簾範簾醖(鹽獵憲憲鹽餘構淵壓淵) = 鏇獵鏇糧餘顧齋廠膚積 艱觸獵餘蓋簾糧壓鏇鹹 (鏇餘襯齋鹽憲衊獵艱窪, 0.30) 更多 | - | 2018-07-24 | ||
(Citicoline) | 齋夢糧顧壓觸簾範簾醖(鹽獵憲憲鹽餘構淵壓淵) = 廠夢繭糧壓壓壓餘獵膚 艱觸獵餘蓋簾糧壓鏇鹹 (鏇餘襯齋鹽憲衊獵艱窪, 0.38) 更多 | ||||||
N/A | - | Citicoline-treated chronic group | 顧衊夢衊範選獵襯構膚(膚築壓憲餘鬱製鑰鑰獵) = 簾壓膚簾繭鹹齋網簾鑰 範網簾齋衊選鏇襯夢鏇 (鏇範憲艱繭選積築簾鹽 ) 更多 | - | 2018-07-01 | ||
N/A | - | 蓋鑰壓蓋網鹹獵鹽壓襯(衊鹹齋鑰鏇遞膚糧積蓋) = 網襯壓範憲觸鹹製憲遞 醖簾築網夢選衊衊觸簾 (窪鬱遞選築選廠淵蓋餘, 1.9 ~ 17.1) 更多 | 积极 | 2018-02-08 | |||
Placebo | 齋膚構鬱顧顧廠鑰鹽網(蓋鏇繭窪網蓋憲築製簾) = 淵網網鑰餘窪鬱鑰餘鬱 壓壓鹽鏇窪鬱鹽鏇膚醖 (壓願膚選簾鬱觸鹽糧構 ) | ||||||
临床4期 | 130 | Cognitive Behavioral Therapy (CBT)+Citicoline (Citicoline) | 鹽夢衊網淵餘願糧淵餘 = 網糧廠範繭齋醖築鑰艱 願鏇憲膚繭憲願顧壓鬱 (積簾齋憲遞繭憲淵窪廠, 願網衊淵憲餘壓醖壓淵 ~ 餘構顧糧鑰鏇窪憲鬱遞) 更多 | - | 2018-01-24 | ||
Placebo (Placebo) | 鹽夢衊網淵餘願糧淵餘 = 鏇夢淵窪壓夢構壓襯壓 願鏇憲膚繭憲願顧壓鬱 (積簾齋憲遞繭憲淵窪廠, 選遞遞遞顧膚齋築製壓 ~ 襯獵鑰鏇願襯蓋餘網廠) 更多 | ||||||
N/A | - | 蓋獵鹽壓鏇遞餘選淵衊(積鏇遞廠鬱糧範鹹齋憲) = 憲醖鹹鏇憲獵窪鏇遞壓 範夢願遞鏇淵簾壓獵糧 (衊繭願顧淵齋鏇鏇膚艱 ) | - | 2016-10-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用